Literature DB >> 18212541

Retiform hemangioendotheliomas usually do not express D2-40 and VEGFR-3.

Amy Parsons1, Daniel Joseph Sheehan, Omar P Sangueza.   

Abstract

Retiform hemangioendothelioma (RH) is a rare vascular neoplasm most often occurring in the limbs of middle-aged females. This entity is characterized by infiltrative vascular spaces arranged in a pattern similar to the rete testis. RH differs from angiosarcoma by lacking cytologic atypia and high mitotic rates. This neoplasm frequently recurs but rarely metastasizes. RH tumor cells react with vascular endothelial markers CD31, CD34, and factor VIII-related antigen. A review of the English literature provides only one attempt at staining RH with D2-40, a marker of endothelium of lymphatic vessels, which was negative, and one reported staining of RH with lymphatic endothelial marker VEGFR-3, which was positive. The etiology of RH is unknown. RH has previously been considered closely related to Dabska tumors, which are positive for lymphatic endothelial marker D2-40. We stained 4 RHs with mouse monoclonal antibodies against D2-40 and CD31 and 3 of the 4 RHs with vascular endothelial growth factor receptor 3 (VEGFR-3), to further evaluate whether RH had lymphatic differentiation, in addition to vascular differentiation. Three of the 4 RH biopsies failed to demonstrate D2-40, none expressed VEGFR-3, whereas CD31 was strongly positive, suggesting that RH is a vascular entity which usually does not have lymphatic differentiation, but may rarely express D2-40.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18212541     DOI: 10.1097/DAD.0b013e31815ea7c5

Source DB:  PubMed          Journal:  Am J Dermatopathol        ISSN: 0193-1091            Impact factor:   1.533


  7 in total

Review 1.  Malignant Superficial Mesenchymal Tumors in Children.

Authors:  Philippe Drabent; Sylvie Fraitag
Journal:  Cancers (Basel)       Date:  2022-04-26       Impact factor: 6.575

2.  Unresectable retiform hemangioendothelioma treated with external beam radiation therapy and chemotherapy: a case report and review of the literature.

Authors:  Alina Z Hirsh; Weisi Yan; Lihong Wei; A Gabriella Wernicke; Bhupesh Parashar
Journal:  Sarcoma       Date:  2010-09-26

3.  Retiform hemangioendothelioma in the infratemporal fossa and buccal area: a case report and literature review.

Authors:  Il-Kyu Kim; Hyun-Young Cho; Bum-Sang Jung; Sang-Pill Pae; Hyun-Woo Cho; Ji-Hoon Seo; Seung-Hoon Park
Journal:  J Korean Assoc Oral Maxillofac Surg       Date:  2016-10-25

4.  Clinical, dermoscopic and histopathologic findings of retiform hemangioendothelioma.

Authors:  Amanda Mota; Giuseppe Argenziano; Iris Zalaudek; Simonetta Piana; Caterina Longo; Elvira Moscarella; Aimilios Lallas
Journal:  Dermatol Pract Concept       Date:  2013-10-31

5.  Medial canthus retiform hemangioendothelioma.

Authors:  Yasser H Al-Faky; Abdul Rahman Al-Mosallam; Ammar C Al-Rikabi; Mohammed O Al-Sohaibani
Journal:  Indian J Ophthalmol       Date:  2014-04       Impact factor: 1.848

6.  Retiform hemangioendothelioma: an uncommon pediatric vascular neoplasm.

Authors:  Swaroop M Ranga; Nischal C Kuchangi; Vijay S Shankar; K Amita; Basavaraj B Haleuoor; Sathyanarayana D Belagola
Journal:  Indian J Dermatol       Date:  2014-11       Impact factor: 1.494

Review 7.  A case report of retiform hemangioendothelioma as pleural nodules with literature review.

Authors:  Qingqing Liu; Ruoyun Ouyang; Ping Chen; Rui Zhou
Journal:  Diagn Pathol       Date:  2015-10-26       Impact factor: 2.644

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.